Background
==========

Antiretroviral therapy (ART) has significantly reduced the morbidity and mortality of people infected with HIV \[[@B1]\], however, long-term use of ART has been associated with a number of metabolic complications such as dysglycaemia, insulin resistance, dyslipidaemia and lipodystrophy \[[@B2]\]. Lipodystrophy is characterized by either subcutaneous fat loss (lipoatrophy), which is most noticeable in the face, limbs, and buttocks, or fat accumulation (lipohypertrophy) seen in the abdomen, breast or posterior neck, or a combination of both \[[@B3],[@B4]\].

Both subjective and objective methods have been used to diagnose lipodystrophy, resulting in a number of case definitions. The most widely used subjective methods of diagnosis are patient perception and report \[[@B5],[@B6]\], physician examination and report \[[@B7]\], and physician confirmation of patient report \[[@B8]-[@B11]\]. Objective measures include imaging by dual-energy X-ray absorptiometry (DXA) \[[@B6],[@B12],[@B13]\] and computed tomography (CT) scans \[[@B12],[@B14]\]. These imaging measures are expensive and not widely available in resource limited settings. Anthropometric and DXA-derived variables have also been developed, in an attempt to provide standard measures of defining lipodystrophy \[[@B15]-[@B17]\]. Furthermore, criteria established to define lipodystrophy did not include data from any African country. These diagnostic criteria may not be generalizable to sub-Saharan Africans, as there are important ethnic differences in fat distribution, especially in black women who have less visceral adipose tissue and more subcutaneous adipose tissue than white women \[[@B18]-[@B20]\].

Lipohypertrophy does not appear to be an adverse ART reaction as participants on different ART drug regimens gained similar amounts of trunk fat over time \[[@B21]\]. Lipoatrophy, in contrast is clearly an adverse ART reaction. The use of stavudine (d4T) and zidovudine (AZT) is associated with subcutaneous fat loss and is partially reversed after changing to abacavir or tenofovir \[[@B21],[@B22]\]. Lipoatrophy remains common in low and middle income countries where d4T has only recently been phased out and AZT is still widely used \[[@B23]\]. However, even if lipohypertrophy is not associated with ART, lipodystrophy, and lipoatrophy in particular, is independently associated with an increased risk of vascular disease \[[@B24],[@B25]\]. Therefore recognising lipodystrophy is important to identify patients at risk for vascular disease so that screening can be targeted for other vascular risk factors, while recognising lipoatrophy is important so that d4T or AZT can be substituted.

The aim of our study was to develop a simple, objective measure to define lipoatrophy and lipohypertrophy by comparing patient report to anthropometric and DXA-derived variables in a sample of black South Africans on ART.

Results
=======

Participant characteristics are presented in Table [1](#T1){ref-type="table"}. The study sample consisted of 550 participants on ART. Based on patient report, 121 (22%) had lipoatrophy and 157 (29%) had lipohypertrophy. Both lipoatrophy and lipohypertrophy were significantly more common in females than in males (p ≤ 0.001). Participants with lipoatrophy had spent a significantly longer period of time on ART (25 vs. 17 months) and a longer time on d4T (15.5 vs. 13 months).

###### 

Characteristics of participants on ART

  **Variable**                  **Lipoatrophy\***   **P-value\*\***    **Lipohypertrophy\*\*\***   **P-value\*\***                      
  ---------------------------- ------------------- ------------------ --------------------------- ------------------ ------------------ ---------
  Age                             34 \[30--42\]      35 \[30--41\]               0.256              34 \[29--41\]      35 \[30--41\]      0.198
  Current CD4 count             397 \[249--539\]    315 \[218--481\]             0.023             389 \[248--548\]   314 \[220--481\]    0.015
  Time on ART (months)            25 \[14--32\]      17 \[10--27\]               0.001              20 \[12--31\]      17 \[11--28\]      0.080
  Time on Stavudine (months)     15.5 \[10--26\]      13 \[8--19\]               0.004               13 \[8--21\]       13 \[9--20\]      0.961
                                   **n \[%\]**        **n \[%\]**                                    **n \[%\]**        **n \[%\]**          
  Sex                                                                                                                                        
    Males                         12 \[10.34\]       104 \[89.66\]               0.001               15 \[12.93\]      101 \[87.07\]     \<0.001
    Females                       109 \[25.12\]      325 \[74.88\]                                  142 \[32.72\]      292 \[67.28\]         
  Highest standard passed                                                                                                                    
    No schooling                   6 \[18.8\]         26 \[81.3\]                0.289               9 \[28.13\]        23 \[71.88\]      0.272
    Primary school                 14 \[15.4\]        77 \[84.6\]                                    20 \[21.98\]       71 \[78.02\]         
    Secondary school               96 \[23.4\]        315 \[76.6\]                                  121 \[29.44\]      290 \[70.56\]         
    Tertiary                       5 \[31.3\]         11 \[68.8\]                                    7 \[43.75\]        9 \[56.25\]          
  ART Regimen                                                                                                                                
    First-line                    99 \[22.30\]       345 \[77.70\]               0.730              130 \[29.28\]      314 \[70.72\]      0.608
    Second-line                   22 \[20.75\]        84 \[79.25\]                                   27 \[25.47\]       79 \[74.53\]         

\*based on patient report, those with moderate or severe fat loss in 2 or more regions.

\*\*Wilcoxon Rank-sum (Mann--Whitney) tests for continuous variables and chi-square tests for binary variables.

\*\*\*based on patient report, those with moderate or severe fat gain in 2 or more regions.

Anthropometric variables are shown separately for women and men (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} respectively). In women, all median skinfold measurements, with the exception of sub-scapular skinfold thickness, were significantly lower in participants with lipoatrophy compared with those without lipoatrophy. Measurements for waist circumference, waist/hip ratio and supra-iliac skinfold thickness were significantly higher in women with lipohypertrophy compared with those without lipohypertrophy. There were no statistically significant differences in anthropometric variables in males with and without lipoatrophy (Table [3](#T3){ref-type="table"}). Males with lipohypertrophy had a significantly (P = 0.008) greater thigh circumference than those without (13.5 mm vs. 8.1 mm).

###### 

Anthropometric measurements of female participants on ART

  **Variable**                         **Lipoatrophy\***      **P-value\*\***      **Lipohypertrophy\*\*\***    **P-value\*\***                          
  ---------------------------------- --------------------- ---------------------- --------------------------- -------------------- --------------------- ---------
  Height (m)                            1.6 \[1.5-1.6\]       1.6 \[1.5-1.6\]                0.603              1.6 \[1.6-1.6\]       1.6 \[1.5-1.6\]      0.112
  Weight (kg)                         65.4 \[56.0-74.5\]     68.1 \[58.9-80.9\]              0.019             69.5 \[60.7-80.4\]   67.1 \[57.6-79.3\]     0.127
  BMI                                 26.2 \[23.8-29.3\]     27.1 \[24.1-31.6\]              0.036             27.4 \[24.6-31.3\]   26.65 \[23.9-31.2\]    0.187
  Sagittal Abdominal Diameter (cm)    20.5 \[19.0-23.0\]     20.0 \[18.5-23.0\]              0.552               21 \[19--24\]         20 \[18--23\]       0.004
  **Circumferences**                                                                                                                                          
    Waist (cm)                        86.3 \[79.5-96.3\]     87.0 \[78.5-97.0\]              0.704             90.7 \[80.3-98.5\]     86 \[78.4-95\]       0.003
    Hip (cm)                          98.0 \[92.0-104.0\]   102.0 \[95.0-112.0\]            \<0.001             100 \[95--110\]       101 \[94--110\]      0.824
    Waist/hip ratio                   0.90 \[0.83-0.94\]     0.85 \[0.80-0.90\]             \<0.001            0.89 \[0.83-0.93\]   0.84 \[0.79-0.90\]    \<0.001
    Mid-upper arm (cm)                27.0 \[25.0-29.0\]     29.0 \[26.5-32.0\]             \<0.001              28 \[26--32\]         28 \[26--32\]       0.789
    Mid-thigh (cm)                    54.5 \[51.0-59.0\]     57.0 \[53.0-63.0\]             \<0.001              56 \[52--61\]         57\[ 52--63\]       0.589
  **Skinfolds**                                                                                                                                               
    Bicep (mm)                          6.0 \[4.4-8.4\]       8.1 \[5.7-11.7\]              \<0.001             7.1 \[5.2-10.7\]      8 \[5.4-11.45\]      0.189
    Tricep (mm)                        13.3 \[9.5-17.4\]     18.4 \[13.6-26.0\]             \<0.001             16.2 \[12--22\]     18.3 \[13--25.15\]     0.059
    Abdomen (mm)                      20.4 \[11.9-30.0\]     24.4 \[16.8-35.3\]              0.001             24.1 \[15.9-35.8\]   23.6 \[15.0-31.2\]     0.210
    Thigh (mm)                        23.8 \[15.4-32.8\]     34.7 \[24.2-44.7\]             \<0.001            29.8 \[20.5-42.5\]   32.0 \[22.5-43.5\]     0.359
    Sub-Scapular (mm)                 16.9 \[12.5-23.0\]     19.2 \[12.2-28.8\]              0.058              20 \[14.8-29.4\]    18.5 \[11.7-27.1\]     0.050
    Supra-iliac (mm)                   13.2 \[7.7-18.7\]     15.1 \[8.8-22.8\]               0.033             16.6 \[9.9-24.0\]     13.9 \[8.2-21.7\]     0.022
    Calf (mm)                          10.8 \[8.0-17.5\]     17.5 \[12.2-24.2\]             \<0.001            15.6 \[9.2-21.3\]    17.3 \[11.4-23.6\]     0.061

\*based on patient report, those with moderate or severe fat loss in 2 or more regions.

\*\*Wilcoxon Rank-sum (Mann--Whitney) tests for continuous variables and chi-square tests for binary variables.

\*\*\*based on patient report, those with moderate or severe fat gain in 2 or more regions.

###### 

Anthropometric measurements of male participants on ART

  **Variable**                        **Lipoatrophy\***     **P-value\*\***     **Lipohypertrophy\*\*\***    **P-value\*\***                         
  ---------------------------------- -------------------- -------------------- --------------------------- -------------------- -------------------- -------
  Height (m)                           1.7 \[1.6-1.7\]      1.7 \[1.6-1.7\]               0.942              1.7 \[1.6-1.8\]      1.7 \[1.7-1.7\]     0.954
  Weight (kg)                         65.5 \[59.7-68.6\]   63.5 \[57.0-74.4\]             0.895             67.4 \[57.8-78.3\]   62.7 \[57.3-73.4\]   0.408
  BMI                                 23.3 \[20.2-23.9\]   22.4 \[20.6-25.2\]             0.772             23.6 \[21.1-25.5\]   22.3 \[20.5-24.8\]   0.324
  Sagittal Abdominal Diameter (cm)    17.0 \[16.0-19.5\]   18.0 \[17.0-20.0\]             0.384             17.0 \[16.0-22.0\]   18.0 \[17.0-20.0\]   0.967
  **Circumferences**                                                                                                                                     
    Waist (cm)                        81.75 \[77--84.9\]   80.4 \[75.0-90.2\]             0.953             83.8 \[75.0-97.0\]   79.8 \[75.8-89.5\]   0.338
    Hip (cm)                           90 \[87--93.5\]     90.0 \[85.0-97.0\]             0.768             91.0 \[85.0-97.0\]   90.0 \[85.0-96.0\]   0.556
    Waist/hip ratio                   0.89 \[0.85-0.95\]   0.91 \[0.87-0.94\]             0.740             0.93 \[0.86-0.97\]   0.90 \[0.86-0.94\]   0.325
    Mid-upper arm (cm)                27.0 \[24--28.5\]    26.0 \[24.0-29.0\]             0.877             27.0 \[25.0-29.0\]   26.0 \[24.0-29.0\]   0.817
    Mid-thigh (cm)                    50.5 \[43.5-52.5\]   49.0 \[46.0-54.0\]             0.401             49.0 \[46.0-56.0\]   49.0 \[46.0-54.0\]   0.567
  **Skinfolds**                                                                                                                                          
    Bicep (mm)                         3.9 \[3.4-4.2\]      3.5 \[3.0-4.5\]               0.329              4.1 \[3.2-4.8\]      3.5 \[3.0-4.3\]     0.180
    Tricep (mm)                        6.8 \[5.6-8.2\]      6.4 \[5.1-9.3\]               0.921              8.4 \[5.0-11.4\]     6.4 \[5.1-8.7\]     0.444
    Abdomen (mm)                      13.5 \[10.5-16.9\]   12.3 \[8.5-30.1\]              1.00              15.8 \[9.3-28.2\]    12.3 \[8.5 -18.1\]   0.309
    Thigh (mm)                         8.4 \[7.2-14.8\]     8.5 \[6.0-12.4\]              0.490             13.5 \[8.4-21.1\]     8.1 \[6.0-11.3\]    0.008
    Sub-Scapular (mm)                  9.4 \[6.5-13.2\]     8.3 \[6.3-13.4\]              0.605             10.5 \[5.7-18.0\]     8.2 \[6.5-11.1\]    0.770
    Supra-iliac (mm)                   6.3 \[4.4-6.8\]      6.2 \[4.9-9.4\]               0.196              6.4 \[4.7-12.1\]     6.2 \[4.9-8.5\]     0.934
    Calf (mm)                          5.5 \[4.8-9.0\]      5.8 \[4.4-8.2\]               0.739              6.8 \[5.4-10.5\]     5.5 \[4.4-7.7\]     0.094

\*based on patient report, those with moderate or severe fat loss in 2 or more regions.

\*\*Wilcoxon Rank-sum (Mann--Whitney) tests for continuous variables and chi-square tests for binary variables.

\*\*\*based on patient report, those with moderate or severe fat gain in 2 or more regions.

DXA-derived measures are shown for women only (Table [4](#T4){ref-type="table"}), as there were insufficient numbers of men with DXA scans for meaningful analysis. Women with lipoatrophy as well as those with lipohypertrophy, had significantly higher percentage trunk fat/lower limb fat and percentage trunk fat/total limb fat and significantly lower percentage lower limb fat/BMI. Women with lipoatrophy had significantly less percentage limb fat while women with lipohypertrophy had significantly more percentage trunk fat.ROC curves for lipoatrophy and lipohypertrophy were generated and reported in female participants for anthropometric and DXA-derived variables with the highest AUC's (Figure [1](#F1){ref-type="fig"}). For lipoatrophy, the two anthropometric variables with the highest AUC were tricep skinfold thickness (AUC = 0.725) and thigh skinfold thickness (AUC = 0.720) and for lipohypertrophy they were waist/hip ratio (AUC = 0.645) and waist circumference (AUC = 0.589). For lipoatrophy, the two DXA-derived variables with the highest AUC were the percentage of lower limb fat standardised to height (AUC = 0.713) and percentage lower limb fat (AUC = 0.705) and for lipohypertrophy they were percentage trunk fat/percentage total limb fat (AUC = 0.647) and percentage trunk fat/ percentage lower limb fat (AUC = 0.646). An illustration of anthropometric and DXA-derived variables in females is shown in Figure [2](#F2){ref-type="fig"}.

###### 

DXA-derived measurements of female participants on ART

  **Variable**                     **Lipoatrophy\***     **P-value\*\***     **Lipohypertrophy\*\*\***    **P-value\*\***                         
  ------------------------------- -------------------- -------------------- --------------------------- -------------------- -------------------- -------
  **DXA-derived measures**                                                                                                                            
  Arm fat (%)                      37.4 \[30.8-44.1\]   38.3 \[31.8-47.1\]             0.380             39.8 \[31.5-48.3\]   38.1 \[31.7-45.1\]   0.319
  Lower limb fat (%)               37.6 \[31.5-40.6\]   43.4 \[36.6-49.7\]             0.001             39.2 \[33.3-49.7\]   41.8 \[36.3-48.8\]   0.761
  Trunk fat (%)                    34.7 \[29.9-38.0\]   35.1 \[27.9-43.1\]             0.719             37.9 \[30.7-45.3\]   34.4 \[26.6-40.4\]   0.019
  Lower limb fat/ht (%)            23.6 \[19.7-25.4\]   27.4 \[23.4-31.5\]             0.001             25.4 \[21.9-31.1\]   26.5 \[23.2-29.7\]   0.631
  Total limb fat/ht (%)            22.7 \[20.8-27.0\]   25.4 \[22.0-29.9\]             0.015             25.4 \[20.8-31.1\]   25.2 \[21.8-29.1\]   0.825
  Lower limb fat/BMI (%)            1.3 \[1.2-1.7\]      1.6 \[1.3-1.8\]               0.049              1.4 \[1.2-1.6\]      1.6 \[1.3-1.8\]     0.019
  Total limb fat/BMI (%)            1.3 \[1.3-1.6\]      1.5 \[1.3-1.6\]               0.193              1.3 \[1.2-1.5\]      1.5 \[1.3-1.7\]     0.006
  Trunk fat/lower limb fat (%)     0.94 \[0.76-1.15\]   0.83 \[0.66-0.96\]             0.017             0.93 \[0.80-1.10\]   0.81 \[0.66-0.94\]   0.003
  Trunk fat/ total limb fat (%)     1.0 \[0.8-1.0\]      0.9 \[0.7-1.0\]               0.045             0.93 \[0.85-1.03\]   0.85 \[0.72-0.97\]   0.003

\*based on patient report, those with moderate or severe fat loss in 2 or more regions.

\*\*Wilcoxon Rank-sum (Mann--Whitney) tests for continuous variables and chi-square tests for binary variables.

\*\*\*based on patient report, those with moderate or severe fat gain in 2 or more regions.

![ROC curves for the 2 anthropometric and DXA-derived variables with the highest AUC for lipoatrophy and lipohypertrophy in female participants on ART.](1742-6405-11-26-1){#F1}

![Lipoatrophy variables for female participants on ART with ROC AUCs of ≥0.6 and their 95% confidence intervals in descending order of AUC.](1742-6405-11-26-2){#F2}

Optimum cut-points for lipoatrophy and lipohypertrophy variables, based on likelihood ratios, were selected. Table [5](#T5){ref-type="table"} shows the sensitivity, specificity, likelihood ratios and predictive values for the two anthropometric and DXA-derived variables with the highest AUC for lipoatrophy and lipohypertrophy at the optimum cut-points.

###### 

Variables for prediction and classification used to identify lipoatrophy and lipohypertrophy cut-points

  **Lipoatrophy variable cut-point**        **N**   **Sensitivity**   **Specificity**   **Likelihood ratio positive test**   **Likelihood ratio negative test**   **Positive predictive value**   **Negative predictive value**   **% correctly classified**
  ---------------------------------------- ------- ----------------- ----------------- ------------------------------------ ------------------------------------ ------------------------------- ------------------------------- ----------------------------
  Tricep skinfold ≤14.5 mm                   418         0.62              0.71                        2.13                                 0.53                              0.42                            0.85                         68.66\*
  Thigh skinfold ≤28.0 mm                    417         0.67              0.65                        1.93                                 0.51                              0.39                            0.85                         65.70\*
  \% Lower limb fat/height ≤ 24.7            418         0.19              0.85                        1.28                                 0.95                              0.30                            0.76                         68.42\*
  Lower limb fat (%) ≤ 39.1                  418         0.19              0.84                        1.20                                 0.96                              0.29                            0.75                         67.70\*
  **Lipohypertrophy variable cut-point**                                                                                                                                                                                                       
  Waist/Hip Ratio ≥ 0.899                    434         0.44              0.75                        1.75                                 0.75                              0.46                            0.73                        64.75\*\*
  Waist Circumference ≥ 88.5 cm              434         0.57              0.59                        1.40                                 0.73                              0.41                            0.73                        58.53\*\*
  Trunk fat/total limb fat (%) ≥0.8895       172         0.50              0.70                        1.66                                 0.72                              0.38                            0.79                         64.5\*\*
  Trunk fat/leg fat (%) ≥ 0.8816             172         0.72              0.61                        1.84                                 0.46                              0.40                            0.86                         64.0\*\*

\*percentage of those classified with and without lipoatrophy using the new cut-point compared to those defined by subject-report.

\*\*percentage of those classified with and without lipohypertrophy using the new cut-point compared to those defined by subject-report.

Discussion
==========

We showed that simple anthropometric measures were at least as good as DXA-derived measures to diagnose lipoatrophy and lipohypertrophy in African women on ART. The best predictors of lipoatrophy in women were the anthropometric variables tricep and thigh skinfold thicknesses; and the DXA-derived variables percentage lower limb fat and percentage lower limb fat/height. The best predictors of lipohypertrophy in women were the anthropometric variable waist/hip ratio and the DXA-derived variable percentage trunk fat/percentage limb fat. Women with lipoatrophy had considerably smaller limb circumferences, limb skinfold thicknesses and lower percentages of limb fat than women without lipoatrophy, despite similar BMIs. Lipoatrophy and lipohypertrophy were both more common in women than in the small sample of men.

Previous studies, conducted in high-income countries, developed objective measures for lipodystrophy, thus combining lipoatrophic and lipohypertrophic individuals \[[@B15]-[@B17]\]. They proposed the use of fat mass ratio (FMR), defined as the ratio between the percentage of trunk fat mass and the percentage of lower-limb fat mass. We however sought to investigate lipoatrophy and lipohypertrophy as separate entities. Identification of lipoatrophy is important as it is an adverse antiretroviral drug reaction, which improves on switching antiretroviral drugs \[[@B21]\]. Although lipohypertrophy is thought to be a consequence of treating HIV infection rather than an adverse antiretroviral drug reaction \[[@B21]\], like lipoatrophy, it is associated with an increased risk of vascular disease \[[@B26]\] therefore it is worth identifying so that appropriate screening and prevention interventions can be implemented.

Despite the subjective nature of assessing lipoatrophy and lipohypertrophy by using patient self-report, previous studies have shown a strong correlation between patient and physician reported lipodystrophy scores \[[@B27]-[@B29]\]. In South Africa, as well as in many other African countries, nurses, rather than physicians, prescribe antiretroviral therapy and follow up patients. For these reasons we used patient self-report \[[@B5],[@B6]\] as the reference measure to define lipoatrophy and lipohypertrophy.

Our study, like several others \[[@B11],[@B21]\], showed a significant association between lipoatrophy and time on ART, and time on d4T in particular. As South Africa has only recently phased out d4T, and AZT is still being used, it is not unexpected that a quarter of the women and a tenth of the men, had lipoatrophy. The prevalence of lipoatrophy found in this study is not easy to compare with other studies as studies from high-income countries focussed on men \[[@B12],[@B24]\], while most studies from Africa looked at the prevalence of lipodystrophy \[[@B30]-[@B32]\] rather than studying the two entities of lipoatrophy and lipodystrophy separately. Our finding that tricep skinfold thickness was a predictor of lipoatrophy is supported by other studies. George et al. \[[@B33]\], using a small sample of HIV-infected South Africans, found that after 2 years of exposure to ART, patients had significantly decreased tricep skinfold thicknesses. Similarly, a Ugandan study using a sample of HIV-infected men and women \[[@B32]\], found that decreased tricep skinfold thicknesses was associated with the use of AZT.

There were some limitations to our study. The cross sectional design, while allowing us to make associations, does not allow us to infer causality. With changes in fat distribution, repeated objective measures would have given us a better reference standard than patient report, even though patient report is commonly used \[[@B5],[@B6]\]. We did not have enough men with lipoatrophy or lipohypertrophy, to explore predictive anthropometric and DXA-derived variables. Finally, the likelihood ratios for the most predictive anthropometric and DXA-derived variables were only weakly diagnostic of self-report lipoatrophy and lipohypertrophy. Future research of longitudinal studies in African cohorts, using changes in DXA-derived variables as the reference standard, is needed to confirm the value of anthropometric measures for the diagnosis of lipoatrophy and lipohypertrophy.

Conclusion
==========

Using a large sample of black HIV-infected South African women who had DXA scans performed, we were able to develop anthropometric measures for defining lipoatrophy and lipohypertrophy. The development of anthropometric measures which admittedly needs training and well maintained skinfold callipers to ensure their accuracy, are of particular relevance in resource limited settings, where health professionals need simple and inexpensive methods of diagnosing patients with lipoatrophy and lipohypertrophy.

Methods
=======

Participants
------------

A convenience sample of HIV-infected black men and women presenting to ART clinics in Cape Town were selected. The recruitment procedure is described elsewhere \[[@B34]\]. The study sample comprised 116 male and 434 female participants on ART. At the time of the study two ART regimens were available to South Africans accessing primary health care facilities. The first-line regimen consisted of d4T, lamivudine (3TC) and efavirenz (EFV) or nevirapine, and a second-line regimen consisting of AZT with 3TC and lopinavir/ritonavir (LPV/r) \[[@B35]\].

Testing procedures
------------------

Questionnaires were used to collect socio-demographic information from participants. Their clinical records at the health facilities were reviewed to obtain data on ART regimen, time on ART, and CD4 count. Self-reported information on fat gain or fat loss was collected using a standard questionnaire \[[@B8]\]. Lipoatrophy was defined as moderate or severe fat loss in 2 or more regions and lipohypertrophy defined as moderate or severe fat gain in two or more areas \[[@B36]\].

Anthropometric measurements: \[weight, height, circumferences (waist, hip, mid-upper arm, and mid-thigh), skinfold thickness (bicep, tricep, subscapular, abdomen, suprailiac, thigh and calf) and sagittal abdominal diameter (SAD)\] taken have previously been described \[[@B37]\]. DXA (Hologic Discovery-W, software version 12.7; scan region 195 × 65 cm^2^ and weight limit 160 kg) was used to measure fat mass and fat free soft tissue mass in a subsample of participants (females: n = 172; males: n = 53). DXA cut off lines positioned at anatomical markers were used to obtain fat mass for the whole body as well as for the various regions of interest. A more detailed description has been previously described \[[@B34]\].

Ethical approval
----------------

The study proposal was submitted and approved by the Research Ethics Committee of the Faculty of Health Sciences at the University of Cape Town. Written informed consent was obtained from all participants prior to participation in the study.

Data analyses
-------------

Data analysis was carried out using the STATA/SE statistical software package version 12.0 (StataCorp., College Station, TX, USA). Data were collected between February 2007 and June 2009. Participants were categorised into those with and those without lipoatrophy. Continuous variables were described as medians and inter-quartile ranges (IQR), and were compared using Wilcoxon Rank Sum tests. Binary variables were described using chi-square tests.

Receiver operating characteristic (ROC) curves were used to describe the performance of a number of anthropometric and DXA-derived variables using patient reported lipoatrophy and lipohypertrophy as the reference standard. The area under the curve (AUC) was used to assess the diagnostic performance of each variable. In addition, sensitivity, specificity, likelihood ratios and predictive values were calculated for variables with the highest AUC at the optimum cut-points. Cut-point selection was based on positive likelihood ratios.
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